The University of Chicago Header Logo

Connection

S. Murray Sherman to Neoplasm Staging

This is a "connection" page, showing publications S. Murray Sherman has written about Neoplasm Staging.
Connection Strength

0.201
  1. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):44-53.
    View in: PubMed
    Score: 0.076
  2. Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis. Thyroid. 2015 Oct; 25(10):1097-105.
    View in: PubMed
    Score: 0.076
  3. The cost, survival, and quality-of-life implications of guideline-discordant imaging for prostate cancer. Cancer Rep (Hoboken). 2022 02; 5(2):e1468.
    View in: PubMed
    Score: 0.028
  4. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep; 17(9):1272-82.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.